Development Of Immunization Policy And Its Implementation In The United Kingdom
- 1 May 2005
- journal article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 24 (3) , 744-754
- https://doi.org/10.1377/hlthaff.24.3.744
Abstract
The U.K. immunization program is managed through a tightly connected process that links the ways policy is developed, submitted to independent expert review and recommendation, adopted into strategy, and implemented into practice. There is one advisory body for immunization. Its recommendations, once accepted by government, are centrally funded, and vaccines are provided at no cost to recipients. Although the present system has worked well, changes in health care management at the peripheral level mean that the immunization program will need to adapt to retain the health gains achieved. Rates of vaccine-preventable disease are at historically low levels, although challenges related to costs and effectiveness remain.Keywords
This publication has 11 references indexed in Scilit:
- Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and WalesVaccine, 2004
- Otitis mediaThe Lancet, 2004
- Varicella vaccination in England and Wales: cost-utility analysisArchives of Disease in Childhood, 2003
- Contacts with varicella or with children and protection against herpes zoster in adults: a case-control studyThe Lancet, 2002
- Vaccine programmes and policiesBritish Medical Bulletin, 2002
- Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and WalesBMJ, 2002
- The potential cost-effectiveness of acellular pertussis booster vaccination in England and WalesVaccine, 2001
- Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success storyVaccine, 2001
- Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in EnglandThe Lancet, 2001
- Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performanceVaccine, 1997